Tumor Microenvironment and Angiogenesis
The DOI matches its Crossref record.
Abstract
References .......................................................................................................................... 142 The major clinical challenge of systemic cancer therapy is not eradication of the primary tumor, which can be treated with radiation or surgery, but eradication of metastases, which are usually present at the time of initial diagnosis and are likely to be resistant to conventional chemotherapy (1-3). A principal barrier to the destruction of disseminated cancer is the heterogeneous nature of cancer. This heterogeneity is exhibited in a wide range of biologic entities such as cell-surface receptors, enzymes, and karyotypes, and in cellular features, such as morphologic characteristics, growth properties, sensitivity to chemotherapeutic drugs, and the ability to invade and metastasize (3,4-6). Neoplastic transformation involves genetic alterations, such as the activation or dysregulation of oncogenes (7), and cells that are able to circumvent normal growth-control mechanisms may undergo continuous selection pres- sures. Unfortunately, this continuous evolution of genetically unstable neoplasms eventually favors the emergence of subpopulations of cells with metastatic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Bremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
Piccard, H., Muschel, R. J., & Opdenakker, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.06.004 · Cited by 373
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer
Unterleuthner, D., Neuhold, P., Schwarz, K., Janker, L., Neuditschko, B., Nivarthi, H., Crncec, I., Kramer, N., Unger, C., Hengstschläger, M., et al. (2020) · Angiogenesis · doi:10.1007/s10456-019-09688-8 · Cited by 299
Xu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., Wang, W., Gao, Z., & Wang, Q. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.045 · Cited by 295
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedRecent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
Dissanayake, S., Denny, W. A., Gamage, S., & Sarojini, V. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.006 · Cited by 280
Contribution of bone microenvironment to leukemogenesis and leukemia progression
Ayala, F., Dewar, R., Kieran, M., & Kalluri, R. (2009) · Leukemia · doi:10.1038/leu.2009.175 · Cited by 273
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
Su, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L., & Yang, S.-F. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1113260 · Cited by 145
Correa de Sampaio, P., Auslaender, D., Krubasik, D., Failla, A. V., Skepper, J. N., Murphy, G., & English, W. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030753 · Cited by 127
Jiménez-Torres, J. A., Virumbrales-Muñoz, M., Sung, K. E., Lee, M. H., Abel, E. J., & Beebe, D. J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.026 · Cited by 46
Metadata
- Venue
- Antiangiogenic Cancer Therapy
- Publisher
- CRC Press
- Published
- 2007-07-25
- Pages
- 149-166
- OpenAlex
- W4247712778
- Cited by
- 145
- References
- 0
- FWCI
- 17.03
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.